By Daniella Parra Aktis Oncology said AKY-1189 is showing promise to treat cancers such as metastatic urothelial carcinoma, breast, lung, colorectal and cervical cancers. The company said data from an oral plenary and two posters highlighted significant tumor uptake and...

By Karen Roman Biotechnology company Medera Inc. said it will start the Cohort B (high-dose) trial of SRD-002, the first-in-human cardiac gene therapy for Heart Failure with Preserved Ejection Fraction. The company finished Cohort A (low-dose) with favorable efficacy results after...

By Daniella Parra March Biosciences has closed an oversubscribed $28.4 million Series A financing, led by Mission BioCapital and 4BIO Capital to advance its innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy and more, it said. The therapy is aimed...

By Karen Roman MOBILion Systems, Inc. revealed its hi-res mass spectrometry functionality with implementations for proteomics, metabolomics and lipidomics, among others. The company’s approach is up to 5-10 times faster than current systems, close to 100% ion utilization efficiency and it...

By Karen Roman Global surgical robotics company CMR Surgical said the FDA has granted marketing authorization for its Versius Surgical Robotic System in the U.S.   Versius is the world’s second most utilized surgical robotic system with over 26,000 procedures...

By Karen Roman Diagnostics company SkylineDx said it will present clinical data on the success of its Merlin test at the 21st International Congress of the Society for Melanoma Research 2024 in New Orleans. The CP-GEP Merlin test accurately stratifies...

By Daniella Parra Recordati said it will acquire the global rights to Enjaymo, used to treat a rare blood disorder, from Sanofi. Enjaymo has been approved by the FDA, European Commission, and Japan’s Ministry of Health, the company said. Recordati...

By Karen Roman Eliem Therapeutics, Inc. (Nasdaq: ELYM) said its new corporate name will be Climb Bio, Inc. and it will start trading at Nasdaq with the ticker symbol “CLYM” on Oct. 3. This rebranding reflects Climb’s laser-focused mission on...

By Karen Roman Aktis Oncology said it raised $175 million in Series B financing, led by RA Capital Management, with RTW Investments and Janus Henderson Investors as co-leads. The capital will contribute to the company’s radiopharmaceuticals pipeline including AKY-1189, its...

By Daniella Parra Vivani Medical said it received regulatory approval in Australia for its GLP-1 (exenatide) implant, aimed at treating obese and overweight individuals. The trial will evaluate the safety, tolerability and pharmacokinetic profile of the implant, which is designed...